Introduction
An estimated 65,340 Americans will be diagnosed with kidney cancer and 14,970 will die of the disease in the USA in 2018. 1 Approximately 90% of renal tumors are renal cell carcinoma (RCC), and approximately 80% of these are clear cell carcinoma. 2, 3 RCC comprises approximately 3.8% of all new cancers, with a median age at diagnosis of 64 years. Younger age at diagnosis has been demonstrated to be a significant prognostic factor for cancer-specific survival (CSS) in numerous malignancies. [4] [5] [6] [7] [8] [9] [10] With respect to kidney cancer, previous studies reported that younger patients had a favorable histological subtype and pathological features with better survival than older patients, [11] [12] [13] [14] [15] [16] although no difference in prognosis between young and old patients with RCC has been reported.
Statistical analysis
CSS was calculated from the date of diagnosis to the date of cancer-specific death. Deaths attributed to kidney cancer were treated as events and deaths from other causes were treated as censored observations. The intergroup comparison of clinicopathologic variables were performed with the chisquared test. Survival was analyzed using the Kaplan-Meier method. 22 The association between each of the potential prognostic factors and the estimated CSS was tested with the log-rank test. 23 Multivariate analysis was performed using the Cox regression model. 24 HRs and 95% confidence intervals for cancer-specific death associated with age were calculated using Cox proportional hazards models for patients diagnosed during the time periods 1995-1999, 2000-2004, and 2005-2009 , which were compared to those diagnosed at baseline, 1990-1994. Cox proportional hazards models were also used to calculate trend tests to calculate P-values for improvements in cancer survival. All models were adjusted for sex, race (white, black, or other), marital status at diagnosis (married, ever married, or never married), histologic type (clear cell carcinoma or non-clear cell carcinoma), pathological grade (grade I, II, III, or IV), SEER historic stages (localized, regional, and distant), age (20-49, 50-64, 65-74, or 75-84 years) and year at diagnosis (1990-1994, 1995-1999, 2000-2004, or 2005-2009 ). "Percentage by age" was calculated as the number of patients diagnosed at a certain age divided by the total number of kidney cancer patients in the database. GaussAmp nonlinear fitting (normal distribution fitting) was performed using the following formula (Equation 1):
( ) The GaussAmp fitted curves for different diagnosis periods were plotted using one coordinated system to enable simple visualization and intuitive distribution comparisons. The area under each fitted curve was painted a different color. The statistical test was two-sided and P<0.05 was considered statistically significant. PASW Statistics 19 (SPSS Inc., Chicago, IL, USA) was used for the statistical analysis. Figure plotting and GaussAmp fitting were performed using Origin Pro version 2017 (OriginLab Corporation, Northampton, MA, USA). 
Results

Patient characteristics
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Disparities of age-based survival improvement in kidney cancer 12-49 years slightly increased, with the most demonstrable change in patients aged 50-64 years. In contrast, the percentage of patients aged 65-74 years decreased over time. The percentage of patients aged 75-84 years remained relatively stable over the 20-year period ( Figure 1 ). Moreover, as judged by the distribution of patients by age at diagnosis using a GaussAmp fitting curve, a tendency for younger-age kidney cancer morbidity was observed ( Figure 2 ). The 8-year CSS was 79.6% for those aged 12-49 years, 70.6% for 50-64 years, 65.3% for 65-74 years, and 56.0% for 75-84 years, which was significant as judged by the univariate log-rank test (P<0.001; Figure 3 ). As judged by univariate analysis, significant risk factors for poor survival (all P<0.001) involved the following categories: male, higher tumor grade, ever married at diagnosis, distant stage, earlier year of diagnosis, and nonclear cell carcinoma (Table 2) . When multivariate analysis with Cox regression was performed, these risk factors were convinced as independent prognostic factors ( 
Discussion
To our knowledge, this is the first large population-based study to evaluate the prognostic impact of age at diagnosis and the importance of clinicopathologic characteristics for kidney cancer survival using the SEER-registered database.
The conventional peak for RCC onset is in the seventh decade of life with only 3%-5% of RCC diagnoses in patients <40 years of age. 25 Previous studies have shown that the mean age for diagnosis of kidney cancer has decreased from 64.7 to 62.7 years with the proportion of patients diagnosed before age 65 increased from 45.9% to 55.3% during the period from 1975 to 2006. 26 Furthermore, overall renal cancer diagnosis in the youngest age group (20-39 years) increased more quickly than all other age groups. In this study, the median age at diagnosis was 62 years with a tendency for younger cancer morbidity.
Analysis of the SEER database indicates that the 5-year survival for localized cancer has increased from 88.4% (1992-1995) to 92.6% with advanced disease increasing from 7.3% to 11.7% (2007-2013 Similar to those results, this study found that all age groups showed improved kidney cancer survival from 1990 to 2009. It is worth noting that survival improvement was greatest for younger age groups than for elderly patients. Improvements in survival are attributed to improved cancer screening, as well as advances in cancer treatments (surgery, radiotherapy, 
29-31
Like most malignancies, the most important prognostic factors at diagnosis for kidney cancer survival are tumor stage, pathological grade, local extent of tumor, regional lymph node involvement, and evidence of metastatic disease. Patient age at diagnosis of kidney cancer has been investigated with inconsistent results. Most investigations have found that younger patients present with a lower tumor stage and with a higher likelihood for nephron sparing surgery than older patients. A few investigations have compared kidney cancer survival rates by sex, actual age, and age at diagnosis, but the importance of age-based survival improvement based on clinicopathologic characteristics is unclear. Muyan Cai et al found that increasing age was associated with a higher incidence of cancer-specific mortality and an age cutoff of 45 years independently predicted CSS of patients with localized RCC. 32 Jung et al reported that young age was an independent prognostic factor for CSS only in low-stage clear cell RCC but not in high-stage clear cell RCC. 16 In agreement with these findings, this study showed a significant age-based survival improvement only in localized stage disease, but 
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Disparities of age-based survival improvement in kidney cancer not in regional or distant stage disease. Sangchul Lee et al found that Korean women with RCC had a lower proportion of clear cell but a higher proportion of chromophobe histology and that this histological difference accounted for the better survival rates for Korean women than men. 33 Edward N. Rampersaud et al reported survival advantage for women <42 years and 42-58 years of age, with no advantage for women ≥59 years of age. 34 Age was an independent predictor of disease-specific survival in women, but not in men. After examination of the EUROCARE-4 database, Micheli et al found that a highly significant age-adjusted advantage was observed in women overall, with greater relative survival noted in younger age groups. 35 Interestingly, women suffered a survival disadvantage in comparison to men in the oldest age group (75-99 years of age). These results are similar to this study in that being female was a significant risk factor for survival. However, female patients showed a greater age-based survival improvement than male patients. 28 Similar to these results, this study also showed that age-based survival improvement was more apparent from 2005 to 2009, indicating that younger patients with kidney cancer may benefit more than elderly patients from advances in cancer treatment, including surgery, radiotherapy, chemotherapy, and targeted therapies. Another noteworthy aspect of this study was that no age-based survival improvement was observed specifically in those of the black race or those with pathological grade IV. Studies have shown that white people consistently have a survival advantage over black people, regardless of tumor characteristics or surgical treatment. 36, 37 But the underlying cause for this disparity is unknown and requires further investigation.
The limitations in the study
Although this is a large population-based study, it has several potential limitations. First, the SEER registry does not collect information on the comorbidities, nutritional status, or performance status of the patients. For example, elderly patients may undergo less aggressive treatment due to comorbidities and poor performance status. Moreover, data on individual socioeconomic status, lifestyle factors, and insurance coverage were not available, which may serve as potential confounding factors. Furthermore, the limitation of not having differentiated by T categories or Fuhrman degrees is explicit. Second, analysis of a nonrandomized patient population may introduce selection bias. Finally, the population was sampled over urban and foreign-born populations, which may affect the generalizability of the 
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Disparities of age-based survival improvement in kidney cancer findings to the general US population. However, the power of this study is its strength.
Conclusion
Age is an independent prognostic factor for survival in patients with kidney cancer. Further, clinicopathologic characteristics associated with age-based survival should be considered crucial determinants in the treatment of kidney cancer.
